Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 2
2007 1
2008 2
2009 1
2010 1
2011 3
2012 5
2013 4
2015 7
2016 7
2017 3
2018 3
2019 5
2020 7
2021 3
2022 7
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Uraki R, et al. Among authors: fujisaki s. Nature. 2022 Jul;607(7917):119-127. doi: 10.1038/s41586-022-04856-1. Epub 2022 May 16. Nature. 2022. PMID: 35576972 Free PMC article.
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
Govorkova EA, Takashita E, Daniels RS, Fujisaki S, Presser LD, Patel MC, Huang W, Lackenby A, Nguyen HT, Pereyaslov D, Rattigan A, Brown SK, Samaan M, Subbarao K, Wong S, Wang D, Webby RJ, Yen HL, Zhang W, Meijer A, Gubareva LV. Govorkova EA, et al. Among authors: fujisaki s. Antiviral Res. 2022 Apr;200:105281. doi: 10.1016/j.antiviral.2022.105281. Epub 2022 Mar 12. Antiviral Res. 2022. PMID: 35292289 Free PMC article. Review.
Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States.
Perofsky AC, Huddleston J, Hansen C, Barnes JR, Rowe T, Xu X, Kondor R, Wentworth DE, Lewis N, Whittaker L, Ermetal B, Harvey R, Galiano M, Daniels RS, McCauley JW, Fujisaki S, Nakamura K, Kishida N, Watanabe S, Hasegawa H, Sullivan SG, Barr IG, Subbarao K, Krammer F, Bedford T, Viboud C. Perofsky AC, et al. Among authors: fujisaki s. medRxiv [Preprint]. 2023 Oct 3:2023.10.02.23296453. doi: 10.1101/2023.10.02.23296453. medRxiv. 2023. PMID: 37873362 Free PMC article. Preprint.
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.
Kawaoka Y, Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann P, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Matsubara S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Okuda M, Murakami J, Duong C, Godbole S, Douek D, Watanabe S, Ohmagari N, Yotsuyanagi H, Diamond M, Hasegawa H, Mitsuya H, Suzuki T. Kawaoka Y, et al. Among authors: fujisaki s. Res Sq [Preprint]. 2022 Feb 24:rs.3.rs-1375091. doi: 10.21203/rs.3.rs-1375091/v1. Res Sq. 2022. PMID: 35233565 Free PMC article. Updated. Preprint.
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: fujisaki s. N Engl J Med. 2022 Mar 10;386(10):995-998. doi: 10.1056/NEJMc2119407. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081300 Free PMC article. No abstract available.
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: fujisaki s. N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9. N Engl J Med. 2022. PMID: 35263535 Free PMC article. No abstract available.
Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses.
Takashita E, Murakami S, Matsuzaki Y, Fujisaki S, Morita H, Nagata S, Katayama M, Mizuta K, Nishimura H, Watanabe S, Horimoto T, Hasegawa H. Takashita E, et al. Among authors: fujisaki s. Viruses. 2023 Jan 15;15(1):244. doi: 10.3390/v15010244. Viruses. 2023. PMID: 36680284 Free PMC article.
Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
Shiwa-Sudo N, Sakai Y, Iwata-Yoshikawa N, Watanabe S, Yamada S, Kuroda Y, Yamamoto T, Shirakura M, Fujisaki S, Miyazaki K, Miura H, Nagata S, Fukushi S, Maeda K, Hasegawa H, Suzuki T, Nagata N. Shiwa-Sudo N, et al. Among authors: fujisaki s. J Virol. 2023 Jan 31;97(1):e0136622. doi: 10.1128/jvi.01366-22. Epub 2023 Jan 12. J Virol. 2023. PMID: 36633406 Free PMC article.
63 results